Canbridge Pharmaceuticals Inc., of Beijing, and Wuxi Biologics Cayman Inc., of Shanghai, are partnering to develop and commercialize a portfolio of biotherapeutics for the treatment of rare diseases. Wuxi will contribute its discovery, development and manufacturing capabilities, while Canbridge will add its clinical, regulatory and commercial expertise.